Although recent evidence supports a tumor-suppressive role for the GTPase RhoB, little is known about its regulation by signal transduction pathways. Here we demonstrate that Ras downregulates RhoB expression by a phosphatidylinositol 3-kinase (PI3K)-and Akt-but not Mek-dependent mechanism. Furthermore, genetic and pharmacological blockade of PI3K/Akt results in upregulation of RhoB expression. We also provide evidence for the importance of the downregulation of RhoB in oncogenesis by demonstrating that RhoB antagonizes Ras/PI3K/Akt malignancy. Ectopic expression of RhoB, but not the close relative RhoA, inhibits Ras, PI3K, and Akt induction of transformation, migration, and invasion and induces apoptosis and anoikis. Finally, RhoB inhibits melanoma metastasis to the lung in a mouse model. These studies identify suppression of RhoB as a mechanism by which the Ras/PI3K/Akt pathway induces tumor survival, transformation, invasion, and metastasis.
RhoB shares 86% amino acid sequence identity with RhoA, yet the roles of these low-molecular-weight GDP/GTP binding GTPases in oncogenesis are quite different. While RhoA, like other GTPase family members such as Ras, Rac1, and Cdc42, promotes oncogenesis, invasion, and metastasis (23, 33, 39, 40) , emerging evidence points to a tumor-suppressive role for RhoB (7, 10-12, 27, 28) . For example, RhoB, but not RhoA, inhibits proliferation, induces apoptosis, and inhibits tumor growth in a nude mouse xenograft model (7, 11, 12) . Consistent with the tumor-suppressive activity of RhoB is the finding that in lung as well as head and neck and brain cancer patient biopsies, RhoB expression is dramatically decreased as tumors become more aggressive (1, 13, 30) . Furthermore, preclinically, RhoB, unlike RhoA, which is constitutively expressed, has been shown to be induced by physical (UV and ␥ irradiation) and chemical (H 2 O 2 , methyl methanesulfonate, and cisplatin) agents (15, 16) . Interestingly, RhoB is also induced by growth factors such as epidermal growth factor (EGF) and plateletderived growth factor (PDGF) (18) . Finally, RhoB appears to be required for stress-induced apoptosis, as cultured fibroblasts derived from RhoB Ϫ/Ϫ knockout mice are resistant to physical and chemical agent-induced apoptosis (27, 28) . Taken together, the evidence points to RhoB as a gene that may play a critical role in protecting cells against stress as well as a novel role as a gene with tumor-suppressive activity. This prompted us to suggest that certain oncogenic and tumor survival pathways that become aberrantly activated during cancer progression may have to overcome RhoB tumor-suppressive activity as one of the steps leading to oncogenesis.
Two major pathways believed to play a pivotal role in human cancer progression are the phosphatidylinositol 3-kinase (PI3K)/Akt and the mitogen-activated Mek/extracellular signal-related kinase (Erk) pathways (8) . Both of these pathways are activated by the low-molecular-weight GTP/GDP binding GTPase Ras, which is found oncogenically mutated in 30% of all human cancers (3) . The ability of the Ras/Raf/Mek/Erk and Ras/PI3K/Akt pathways to induce uncontrolled deregulated proliferation and tumor survival in human cancer cells may depend not only on activating genes that stimulate cellular proliferation and survival but also on antagonizing those genes that suppress proliferation and/or induce apoptosis. Recently we have shown that EGF receptor (EGFR), ErbB2, and Ras but not Src inhibit RhoB expression (21) . In this article, we demonstrate that oncogenic Ras downregulates RhoB expression by a PI3K-and Akt-but not a Mek-dependent mechanism. Furthermore, ectopic expression of RhoB, but not its close relative, RhoA, antagonizes Ras/PI3K/Akt-dependent transformation, apoptosis resistance, migration, and invasion as well as metastasis in an animal model.
HA-tagged pcDNA3 (10, 23, 34 (25) , and Akt constructs were originally provided by Jin Cheng (20) . ␤-Galactosidase activity and luciferase assay kits were purchased from Promega Corporation, Madison, Wis. The serum response element (SRE) reporter has been described before (21) . DNA transfection was performed according to the Trans-IT-3T3 protocols for NIH 3T3 and H-Ras/NIH 3T3 cells or Trans-IT-LT1 protocols for PANC-1 cells (Mirus Corporation, Madison, Wis.). For B16-F10 cells, DNA transfection was performed with standard Lipofectamine protocols (Invitrogen, Grand Island, N.Y.). RhoB and SRE promoter transcriptional activity assays were performed according to the protocols accompanying the kits (Promega Corporation, Madison, Wis.). All the samplings were performed in triplicate, and the averages of three independent experiments are reported here. Focus formation assay. NIH 3T3 cells were seeded into 60-mm-diameter plates, and each plate was transfected with 0.1 g of each oncogene construct plus 0.9 g of pcDNA-RhoA, pcDNA-RhoB, or pcDNA3 vector control. Two days later, the cells were seeded into 60-mm-diameter plates at a density of 2.5 ϫ 10 3 cells per plate and maintained in DMEM containing 1.5% calf bovine serum. The medium was changed every 3 days. Four weeks later, the cells were fixed, stained with crystal violet solution, and photographed. All the samplings were performed in triplicate, and a representative of three independent experiments is reported here.
Cell migration and invasion assay. Cellular migration and invasion assays were performed with conventional Boyden transwell methods. Briefly, the cells were transfected and serum starved overnight and then treated with either dimethyl sulfoxide (DMSO) vehicle control or LY294002 (20 M) or PD98059 (20 M) for 30 min. Equal numbers of cells were added to the upper side of the transfilter (poly-hydrocarbonate membrane, 6-m pore size) precoated with collagen type I for migration assays or reduced Matrigel plus collagen type I for invasion assays and placed in a 37°C tissue culture incubator for 12 h (H-Ras/ NIH 3T3) or 8 h (PANC-1). The cells that migrated to the lower surface of the transfilter were stained and counted to determine the effect of a transfected gene or the inhibitor treatment.
Western blot analysis. Whole-cell lysates were prepared in a lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, 1.5 g each of aprotinin and leupeptin per ml, 10 mM NaF, and 10 mM NaPPi. Fifty micrograms of the lysates was loaded into sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and analyzed for each sample. Antigen-bound antibody was detected with an enhanced chemiluminescence Western blotting kit (Amersham Pharmacia Biotech, Piscataway, N.J).
Cell proliferation and apoptosis assay. Cells were collected and stained with annexin V and 7-AAD according to the manufacturer's recommendation (PharMingen, San Diego, Calif.). Data acquisition and analysis were performed by the Flow Cytometry Core Facility at the H. Lee Moffitt Cancer Center. In parallel, cells were also examined for cell number and viability by trypan blue exclusion and hemocytometer counting at the time intervals as indicated. All samplings were performed in triplicate, and the averages of three independent experiments are reported.
Anoikis assay. The tissue culture plates were precoated twice with 50 mg of poly-(2-hydroxyethyl methacrylate) (poly-HEMA) ml Ϫ1 (Sigma, St. Louis, Mo.). The cells were washed in serum-free medium and seeded onto the precoated plates, and viability was examined at different time points by apoptotic assays with annexin V and 7-AAD labeling as described above. All samplings were performed in duplicate, and a representative of three independent experiments is reported here.
Melanoma metastasis assay. pcDNA3, pcDNA-RhoB, and pcDNA-RhoA were transfected into B16-F10 cells as described above. The cells were harvested 20 h posttransfection, 5 ϫ 10 5 cells from each group were analyzed for transfection efficiency by Western blotting, and another 5 ϫ 10 5 cells were injected into the tail veins of C57/BL6 mice (6-week-old females). The mice were sacrificed after 21 days, and the nodules growing in the lungs were counted.
RESULTS
Ras downregulation of RhoB promoter transcriptional activity is mediated by PI3K and Akt but not Mek1/2. The fact that RhoB has tumor-suppressive activity (7, 11, 12) and that RhoB levels decrease dramatically with the aggressiveness of tumors (1, 13, 30) prompted us to test the hypothesis that oncogenic and tumor survival pathways downregulate RhoB as a step leading to malignant transformation. Recently we have shown that EGFR, ErbB2, and Ras but not Src inhibit RhoB expression (21) . Here we investigated the role of the PI3K/Akt and Mek limbs of the Ras pathways in this RhoB downregulation. To this end, NIH 3T3 cells were transfected with a RhoB promoter firefly luciferase reporter and SRE-Renilla reporter, along with various DNA constructs as described in Materials and Methods. Figure 1a shows that transfection with oncogenic H-Ras resulted in a 78% inhibition of RhoB promoter activity. This suppression of RhoB promoter activity was rescued in a concentration-dependent manner by dominantnegative forms of PI3K (DN-PI3K) and Akt1 (DN-Akt), suggesting that PI3K and Akt1 are required for H-Ras to inhibit RhoB promoter activity. Similar results were obtained with DN-Akt2 (data not shown). Figure 1a also shows that while DN-PI3K and DN-Akt inhibited the ability of Ras to suppress RhoB promoter activity by 79 and 76%, DN-Mek1/2 was only able to inhibit activity by 30%. In contrast, the ability of Ras to induce SRE promoter activity was equally inhibited by DN-PI3K, DN-Akt, and DN-Mek1/2. Therefore, the Ras suppression of RhoB promoter activity is primarily mediated by the PI3K/Akt pathway. Consistent with this is the demonstration that constitutively activated forms of PI3K (CA-PI3K) and Akt1 (CA-Akt), but not CA-Mek1/2, inhibited RhoB promoter activity (Fig. 1b) . Finally we have also shown that the downregulation of RhoB by two receptor tyrosine kinases, EGFR and ErbB2, also requires PI3K and Akt, but not Mek (data not shown). To document that the CA and DN forms of PI3K, Akt, and Mek1/2 as well as H-Ras are expressed and that their expression results in their intended effects, we have blotted the lysates from the various conditions with antibodies that recognize P110, Akt, Mek, P-Akt, and P-ERK as well as antibodies that recognize HA (H-Ras) and actin ( Fig. 1a and b) .
Activation of the Ras/PI3K/Akt pathway inhibits the induction of RhoB promoter activity by the anticancer drug 5-FU. Figure 1 demonstrated that the Ras/PI3K/Akt pathway inhibits the basal level (unstimulated) of RhoB promoter transcriptional activity. However, RhoB is usually expressed at very low levels but is induced by physical (UV and ␥ irradiation) and chemical (paclitaxel cisplatin, and H 2 O 2 ) agents (15, 16) . . The cells were then lysed and analyzed for P-Akt, RhoB, and RhoA protein levels by Western blotting with anti-RhoB and anti-RhoA; the same filter was reprobed with anti-␤-actin for a loading control. (c) NIH 3T3 cells were transiently transfected with various genes as indicated for 24 h and then treated with either DMSO vehicle, LY294002, or 5-FU alone or in combination for another 48 h. The cells were analyzed for P-Akt, RhoB, RhoA, and ␤-actin protein levels as described above. (d) PANC-1 cells were transiently transfected with DN-Akt1 and DN-Akt2 genes as indicated for 24 h and then treated with either DMSO vehicle or 5-FU alone or in combination for another 48 h. The cells were analyzed for P-Akt, RhoB, and RhoA protein levels by Western blotting with anti-P-Akt, anti-RhoB, and anti-RhoA; the same filter was reprobed with anti-␤-actin, anti-HA, and anti-pan-Akt antibodies. PANC-1 (e) and A549 (f) cells were treated with PD, LY294002, or 5-FU as indicated for 48 h and then analyzed for RhoB and RhoA protein levels by Western blotting as described above.
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Therefore we next determined whether the Ras/PI3K/Akt pathway also suppresses the induction of RhoB. To this end, NIH 3T3 cells were transfected with RhoB promoter reporter, SRE promoter reporter, and treated with either DMSO or the anticancer drug 5-fluorouracil (5-FU) as described in Materials and Methods. Figure 2a shows that treatment of NIH 3T3 cells with 5-FU induced RhoB promoter activity by twofold, whereas transfection with oncogenic H-Ras, CA-PI3K, and CA-Akt but not CA-Mek1/2 inhibited RhoB promoter activity by 76, 72, and 70%, respectively. Furthermore, in the presence of oncogenic H-Ras, CA-PI3K, or CA-Akt, 5-FU was unable to stimulate RhoB promoter activity (Fig. 2a) . In contrast, CAMek1/2 did not inhibit 5-FU induction of RhoB (Fig. 2a) . Figure 2b shows that 5-FU had little effect on RhoB promoter activity in NIH 3T3 cells that stably express oncogenic H-Ras. (Fig. 2c) .
Blocking the H-Ras/PI3K/Akt pathway induces RhoB protein levels. Figures 1 and 2 demonstrate that the Ras/PI3K/Akt pathway downregulates RhoB promoter transcriptional activity. The relevance of this important finding to endogenous RhoB protein was documented by showing that in the absence of LY294002, H-Ras/NIH 3T3 cells contained phosphorylated Akt (P-Akt) and expressed little RhoB, while treatment with LY294002 inhibited P-Akt levels and increased RhoB protein levels (Fig. 3a) . In contrast, the levels of RhoA, a closely related family member, did not change following LY294002 treatment. Figure 3b shows that the induction of RhoB protein levels was detectable as early as 12 h after LY294002 treatment. We next analyzed parental NIH 3T3 cells and found that 5-FU induces RhoB protein levels and that oncogenic H-Ras, CA-PI3K, and CA-Akt all decreased both basal and 5-FUinduced RhoB protein levels (Fig. 3c) . Treatment with LY294002 sensitizes oncogenic H-Ras-but not CA-Akt-transfected cells to 5-FU induction of RhoB expression, consistent with H-Ras being upstream, whereas Akt is downstream of PI3K, the target for LY294002. Treatment with PD98059 or U0126 (Mek inhibitors) did not sensitize the cells to 5-FU induction of RhoB (data not shown). The relevance of these findings to human cancer cells is documented in Fig. 3d , e, and f. Figure 3d shows that the DN forms of Akt1 and Akt2 induced RhoB protein levels slightly when used alone, but the induction was greater when both DN-Akt1 and DN-Akt2 were transfected into PANC-1 cells. Figure 3d also shows that transfection of PANC-1 cells with both DN-Akt1 and DN-Akt2 sensitized these cells to 5-FU induction of RhoB. Figure 3e shows that treatment of PANC-1 cells with LY294002 induced RhoB, but not RhoA, protein levels by eightfold. Treatment of PANC-1 cells with PD98059 resulted in no induction. Figure 3f shows that in another human cancer cell line, A549, LY294002 treatment similarly sensitized these cells to 5-FU induction of RhoB protein levels. Treatment with 5-FU or LY294002 alone induced RhoB only slightly (1.3-and 1.2-fold, respectively). However, cotreatment with 5-FU and LY294002 induced RhoB protein levels 3.9-fold (Fig. 3f) .
The ability of oncogenic H-Ras, PI3K, and Akt to transform NIH 3T3 cells is antagonized by ectopic expression of RhoB not RhoA. Figures 1 through 3 clearly demonstrate that the H-Ras/PI3K/Akt pathway downregulates RhoB at the promoter as well as the protein levels. If downregulation of RhoB is a critical step for the H-Ras/PI3K/Akt pathway to mediate malignant transformation, then ectopic expression of RhoB should antagonize this transformation. To evaluate this possibility, we transfected NIH 3T3 cells with DNA constructs containing RhoA, RhoB, H-Ras61L, CA-PI3K, and CA-Akt either alone or in combination and monitored the ability of these cells to form foci as described in Materials and Methods. Figure 4a shows that parental NIH 3T3 cells as expected grew no colonies, but those transfected with either H-Ras61L, CA-PI3K, or CA-Akt grew numerous colonies. Cotransfection with RhoB but not RhoA along with the above genes resulted in significant inhibition of colony formation (see actual colony numbers in Fig. 4a ). RhoB and RhoA were expressed at similar levels (Fig. 4a ). The ability of oncogenic H-Ras, PI3K, and Akt to induced migration is inhibited by RhoB not RhoA. Among the hallmarks of malignant transformation is the ability of cancer cells to migrate, invade, and metastasize, and the Ras/PI3K/Akt pathway is well known to be intimately involved in these pro- Figure 4b and c show that mock-, pcDNA3-, and RhoA-transfected as well as DMSOtreated cells migrated (through collagen type I) to the lower side of the transfilter. In contrast, the ability of LY294002-treated H-Ras/NIH 3T3 and PANC-1 cells as well as cells transfected with RhoB was dramatically hindered (see the actual number of cells within each panel of Fig. 4b and c) . Furthermore, CA-Akt or wild-type Akt (WT-Akt) alone or with RhoA enhanced the ability to migrate, while RhoB inhibited the ability of CA-Akt and WT-Akt to enhance cell migration ( Fig. 4b and c) . Using enhanced green fluorescent protein (EGFP) transfections, we have determined transfection efficiencies to be 76% Ϯ 7% and 71% Ϯ 5% for H-Ras/NIH 3T3 cells and PANC-1 cells, respectively ( Fig. 4b and 4c ). The ability of RhoB to inhibit cancer cell migration was further confirmed in a different assay in which cells are induced to migrate by physical wounding of cells plated on fibronectinprecoated plates. Figure 4d shows that 24 h after wounding, NIH 3T3 cells transfected with pcDNA3 were able to grow and fill the wounded area. Figure 4d also shows that oncogenic H-Ras, CA-PI3K, CA-Akt, WT-Akt, and RhoA transfection accelerated whereas RhoB inhibited the wound healing. Furthermore, RhoB also inhibited the ability of oncogenic H-Ras, CA-PI3K, CA-Akt, and WT-Akt to enhance wound healing (see the actual number of cells within each panel of Fig. 4e) .
RhoB, not RhoA, inhibited H-Ras/PI3K/Akt-mediated cell invasion. Figure 4 demonstrated that ectopic expression of RhoB antagonizes cell migration. We next evaluated whether RhoB can also antagonize cell invasion. To this end, H-Ras/ NIH 3T3 and PANC-1 cells were transfected as described in the legend to Fig. 4 with various oncogenes along with RhoA or RhoB and then seeded onto Matrigel-coated poly-hydrocarbonate filters mounted in the middle of a Boyden transwell apparatus as described in Materials and Methods. Figure 5a and b show that mock-transfected or DMSO-treated cells efficiently invaded through Matrigel-collagen. In contrast, LY294002-treated H-Ras/NIH 3T3 and PANC-1 cells did not invade. In addition, cells transfected with pcDNA3 or pcDNA3-RhoA, but not pcDNA3-RhoB, invaded. Furthermore, transfection with CA-Akt or WT-Akt enhanced invasion, and RhoB, not RhoA, inhibited this enhancement of invasion (see the actual number of cells within each panel of Fig. 5a and b) .
RhoB, not RhoA, reverses Ras/PI3K/Akt-mediated resistance to 5-FU-induced apoptosis and protects against anoikis. Another hallmark of cancer cells is to resist apoptosis and promote tumor survival. The ability of 5-FU to induce RhoB is antagonized by the Ras/PI3K/Akt pathway ( Fig. 2 and 3) , and this coupled with the previously reported role of RhoB in apoptosis (7, 27) prompted us to determine the role of RhoB and the Ras/PI3/Akt pathway in 5-FU-induced apoptosis. To this end, NIH 3T3 cells were transiently transfected with pcDNA3, H-Ras61L, Akt, RhoA, or RhoB for 24 h and treated with DMSO vehicle or 5-FU for an additional 48 h and apoptosis was analyzed by annexin V labeling and flow cytometry as described in Materials and Methods. In experiments similar to those of Fig. 4a and b, using EGFP, we have determined the transfection efficiency in NIH 3T3 cells to be 71% Ϯ 6% (Fig.  6a) . Figure 6a also shows that 5-FU treatment induced 28 to 30% apoptosis in NIH 3T3 cells. Transfection with H-Ras61L or Akt decreased the 5-FU apoptosis rate to 15 or 17%, respectively. Furthermore, while RhoA slightly protected it, RhoB enhanced the ability of 5-FU to induce apoptosis (Fig.  6a) . Importantly, RhoB, but not RhoA, reversed Akt-mediated resistance to 5-FU-induced apoptosis.
In addition to 5-FU-induced apoptosis, we examined the effects of RhoB on apoptosis induced by depriving cells from substratum attachment (anoikis). Figure 6b shows that 12 or 24 h after seeding onto poly-HEMA-coated culture plates, RhoB-transfected cells displayed significantly higher cell death induced by lack of attachment than pcDNA3-transfected cells. However, H-Ras61L-, Akt-, and RhoA-transfected cells showed a much lower rate of anoikis. Notably, RhoB reversed Akt-mediated resistance to this type of apoptosis (Fig. 6b) .
RhoB, not RhoA, inhibits melanoma metastasis to the lung in a mouse model. The work described above clearly shows that in cultured cells RhoB is a potent suppressor of transformation, migration, and invasion of cancer cells. To give further support to this in vivo, we transfected the highly metastatic melanoma cells B16-F10 with either pcDNA3, pcDNA3-RhoA, or pcDNA3-RhoB, injected the cells into the tail vein of C57 black mice, and determined lung metastasis after 3 weeks as described in Materials and Methods. First we documented that RhoB expression is regulated by the PI3K/Akt pathway in B16-F10 cells by demonstrating that treatment with LY294002 strongly induced RhoB protein levels (Fig. 6c) . Furthermore, the transfected HA-RhoA and HA-RhoB were readily expressed in B16-F10 cells as determined by Western blotting (Fig. 6c) . Importantly, Fig. 6d shows that pcDNA3-transfected cells were highly metastatic and grew 14.8 Ϯ 1.9 metastatic colonies per lung. Similarly pcDNA3-RhoA-transfected B16-F10 cells grew 13 Ϯ 4.5 colonies per lung. In contrast, pcDNA3-RhoB-transfected B16-F10 cells grew only 2 Ϯ 0.7 colonies.
DISCUSSION
The ability of oncogenic Ras to transform cells depends not only on activating proliferative pathways but also on inhibiting tumor-suppressive pathways. Recently we have shown that EGFR, ErbB2, and Ras, but not Src, inhibit RhoB expression (21) . The work presented in this article provides support for the downregulation of RhoB as one of the steps taken by oncogenic Ras to transform cells and that the PI3K/Akt limb and not the Mek limb of the Ras signaling pathway is the mediator for this downregulation. Furthermore, we demonstrate that ectopic expression of RhoB, but not its close GTPase relative, RhoA, blocks activated H-Ras, PI3K-and Akt-mediated malignant transformation, resistance to anticancer drug-induced apoptosis and anoikis, cell migration, and (Fig. 6e) . Similar results also showed an antagonistic interaction between RhoB and two receptor tyrosine kinases, EGFR and ErbB2 (data not shown). These findings are critical, since they identify RhoB as a negative regulator of Ras, EGFR, and ErbB2, three components of signal transduction that are intimately involved in human cancers, and further suggest that RhoB is functioning as a tumor suppressor against carcinogenesis mediated by receptor tyrosine kinases and their downstream effectors. This is consistent with a recent report showing that RhoB Ϫ/Ϫ mice are more prone to skin chemical carcinogenesis (28) . This is the first report documenting the anti-invasive and antimetastatic activities of RhoB. This is an important finding, since most GTPases studied to date, such as Ras, RhoA, Rac1, and Cdc42, promote rather than inhibit invasiveness and metastasis (4, 17, 19, 22, 35) . The ability of RhoB to inhibit motility, invasion, and metastasis is consistent with the fact that RhoB expression is decreased dramatically as tumors progress from the noninvasive carcinoma stages to the highly invasive, deeply infiltrating and metastatic stage in head and neck, brain, and lung cancer patient biopsies (1, 13, 30) . Furthermore, RhoB decreased the levels of matrix metalloprotease 2 (MMP-2) (data not shown), one of the matrix metalloproteinases that tumors secrete to degrade extracellular matrix components, a step required for tumor cells to migrate and invade surrounding tissue as well as distant sites (24, 36, 42) . PI3K and Akt have recently been shown to induce the expression of MMP-2 and MMP-9 by a mechanism involving Akt activation of NF-B binding to the MMP promoter (24, 32) . Thus, one possible mechanism by which RhoB inhibits tumor migration and invasion is by blocking the ability of the Ras/PI3K/Akt pathway to activate NF-B. Consistent with this is the demonstration by Fritz et al. that ectopic expression of RhoB inhibits NF-B-dependent transcriptional activation (14) . Finally, the PI3K/Akt-induced resistance of nonadherent cells to apoptosis (anoikis) is antagonized by RhoB, giving further support to the notion that the prosurvival Ras/PI3K/Akt pathway must suppress RhoB expression for nonadherent cancer cells to migrate and invade.
Anticancer drug resistance, a major obstacle to cancer treatment, is often due to constitutive activation of the oncogenic and tumor survival pathway, and the Ras/PI3K/Akt pathway is a major contributor to resistance of human cancers to common anticancer drugs such as paclitaxel (5, 29) . In this study, we have shown that this pathway induces resistance to another commonly used anticancer drug, 5-FU. Importantly, ectopic expression of RhoB counteracted Akt-mediated resistance and sensitized cells to 5-FU. Consistent with this is a recent study demonstrating that RhoB Ϫ/Ϫ cells are resistant to radiation and anticancer drug therapy (27) . Taken together, these findings suggest that RhoB can be used in combination therapy studies to overcome anticancer drug resistance.
In summary, we demonstrated that the GTPase RhoB negatively regulates the ability of the Ras/PI3K/Akt pathway to induce transformation, migration, and invasion as well as resistance to anticancer drug apoptosis and nonadherent cell death (anoikis). We further demonstrated that Ras downregulates the expression of RhoB by a mechanism involving PI3K and Akt and not Mek. Based on these results and our recently reported studies of human biopsies, we propose that tumor cells may have to downregulate RhoB expression and thus suppress its ability to inhibit transformation, invasion, and metastasis as one of the steps necessary for reaching a highly malignant phenotype (Fig. 6e) . The discovery of this novel antagonistic interaction between a major oncogenic/tumor survival pathway and RhoB further enhances our understanding of oncogenesis and has far-reaching implications for the treatment of advanced cancer by targeting tumor cell invasion/ metastasis as well as drug resistance.
